Skin Cancer Melanoma Medical Oncology
Sapna Patel, MD, a widely renowned melanoma oncologist and clinical investigator, has joined the University of Colorado Cancer Center and the CU Department of Medicine, with a goal of helping to build a “pinnacle of skin cancer treatment” in the Rocky Mountains.
As spring days get longer and summer approaches, people begin to spend more time outdoors — especially in Colorado, with its 300 days of sunshine per year.
Skin Cancer Melanoma rare disease
Some of the most dramatic scenes in the new Bob Marley biopic, “Bob Marley: One Love” have to do with the reggae legend’s battle with a rare cancer called acral lentiginous melanoma. Unlike melanomas that are caused by sun exposure, acral lentiginous melanomas form on non-hair-bearing surfaces of the body, including the palms of the hand, the soles and heels of the feet, and the nailbeds of the fingers and toes.
University of Colorado Cancer Center member Maryam Asgari, MD, MPH, is one of nine CU School of Medicine faculty members to be awarded an Anschutz Acceleration Initiative grant. The winning projects, announced in January, were chosen for their promise to deliver life-changing advancements in medicine within the next three to five years.
A recent study of a type of immune blood cells associated with resistance to certain treatments for melanoma is one sign of the growing role of data science in solving some of medicine’s most puzzling riddles, says Hatim Sabaawy, MD, PhD, associate director of translational research at the University of Colorado Cancer Center.
Skin Cancer Dermatology skin damage
Colorado is a winter playground, whether your passion is skiing, snowboarding, snowshoeing, or just throwing snowballs. But the bright sun that helps make winter sports in the Rockies so delightful also poses a threat to your skin.
After battling skin cancer for four years before his death, "Margaritaville" singer Jimmy Buffett died on September 1, 2023, at age 76, from Merkel cell carcinoma, according to his website.
Press Coverage Community Skin Cancer
CU Cancer Center member Neil Box, MD, separates fact from pseudoscience when it comes to protecting yourself from the sun.
Community Skin Cancer Magazine Melanoma
CU Cancer Center member Neil Box, PhD, is on a quest to decrease the deadly effects of melanoma.
In the summer of 2019, Dr. Neil Box toured Colorado with the Sun Bus, attending events with over 700,000 participants and reaching 26,000 people in 46 service days. Free skin cancer screens identified 96 suspected skin cancers, including six cases of dangerous melanoma. The tour also gave Dr. Box the opportunity to hear what people think about skin cancer and sun protection.
Patient Care Skin Cancer Magazine Melanoma
“For Christmas, we took a family photo with all the grandkids,” says Sam’s wife, Janet. She went on to explain, “The kids wanted to take this photo because they thought Sam would not be here next Christmas.”
We all know that in the spring or before going on a beach vacation, it’s important to get a solid tan so that we don’t get burned. After all, it’s sun burns and not sun tans that cause skin cancer, right? Not so fast, says Neil Box, PhD, University of Colorado Cancer Center investigator and president of the Colorado Melanoma Foundation.
Research Faculty Skin Cancer Melanoma
It seems like everybody’s got a story about that “one bad burn” – the time you fell asleep next to the pool and tattooed a white handprint on your lobster-red chest, or forgot to pack the sunscreen while hiking a Colorado 14er. As you know, sunburn increases your chance of developing melanoma and other skin cancers. But what about just one bad burn? And what can you do about it now?
A pair of University of Colorado Cancer Center studies published this month show that the milk thistle extract, silibinin, kills skin cells mutated by UVA radiation and protects against damage by UVB radiation – thus protecting against UV-induced skin cancer and photo-aging.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Mark Harden
